Sanofi to acquire Vigil Neuroscience for $8.00 per share, focusing on neurology innovation

From GlobeNewswire: 2025-05-21 19:30:00

Sanofi to acquire Vigil Neuroscience, Inc. for $8.00 per share in cash at closing, with an additional $2.00 per share contingent value right following the first commercial sale of VG-3927. The transaction is expected to enhance the development of the oral small molecule TREM2 agonist program, particularly for Alzheimer’s disease treatment. The deal, totaling approximately $600 million, is set to close in the third quarter of 2025. The acquisition aligns with Sanofi’s strategic focus on neurology and aims to offer innovative therapies to address critical unmet needs in neurodegenerative diseases.



Read more at GlobeNewswire: Vigil Neuroscience Enters into Definitive Merger Agreement